Veracyte, Inc. (VCYT) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
44.23
↓-30% vs avg
5yr avg: 63.26
30Y Low53.1·High73.4
P/FCF
↓
22.73
↓-49% vs avg
5yr avg: 44.54
30Y Low26.8·High58.3
P/B Ratio
↑
2.23
-1% vs avg
5yr avg: 2.25
30Y Low1.1·High6.2
ROE
↑
5.3%
↓+308% vs avg
5yr avg: -2.6%
30Y Low-278%·High5%
Debt/EBITDA
↓
0.69
↓-30% vs avg
5yr avg: 0.98
30Y Low0.7·High1.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Veracyte, Inc. trades at 44.2x earnings, 51% below its 5-year average of 89.5x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.2x, the stock trades at a premium of 91%. On a free-cash-flow basis, the stock trades at 22.7x P/FCF, 49% below the 5-year average of 44.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.9B | $3.4B | $3.1B | $2.0B | $1.7B | $2.8B | $2.6B | $1.3B | $466M | $222M | $223M |
| Enterprise Value | $2.6B | $3.1B | $2.9B | $1.8B | $1.6B | $2.6B | $2.3B | $1.1B | $413M | $213M | $189M |
| P/E Ratio → | 44.23 | 51.34 | 127.74 | — | — | — | — | — | — | — | — |
| P/S Ratio | 5.57 | 6.56 | 6.94 | 5.54 | 5.73 | 12.74 | 22.18 | 10.70 | 5.06 | 3.08 | 3.43 |
| P/B Ratio | 2.23 | 2.59 | 2.63 | 1.91 | 1.58 | 2.55 | 6.19 | 5.38 | 5.84 | 5.95 | 3.75 |
| P/FCF | 22.73 | 26.79 | 48.51 | 58.33 | — | — | — | — | — | — | — |
| P/OCF | 21.12 | 24.89 | 41.22 | 45.19 | 225.33 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Veracyte, Inc.'s enterprise value stands at 44.2x EBITDA, 30% below its 5-year average of 63.3x. The Healthcare sector median is 14.9x, placing the stock at a 197% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.93 | 6.52 | 4.97 | 5.26 | 12.04 | 19.31 | 9.49 | 4.49 | 2.96 | 2.91 |
| EV / EBITDA | 44.23 | 53.12 | 73.41 | — | — | — | — | — | — | — | — |
| EV / EBIT | 44.23 | — | 112.91 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 24.24 | 45.56 | 52.38 | — | — | — | — | — | — | — |
Profitability
Margins and return-on-capital ratios measuring operating efficiency
Veracyte, Inc. earns an operating margin of 11.2%. Operating margins have expanded from -23.8% to 11.2% over the past 3 years, signaling improving operational efficiency. ROE of 5.3% is modest. ROIC of 4.4% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.1% | 70.1% | 66.9% | 68.7% | 65.7% | 66.1% | 64.7% | 69.7% | 64.0% | 60.8% | 60.9% |
| Operating Margin | 11.2% | 11.2% | 3.6% | -23.8% | -13.9% | -37.3% | -30.1% | -12.6% | -24.2% | -36.9% | -44.3% |
| Net Profit Margin | 12.8% | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% | -29.7% | -10.5% | -25.0% | -43.1% | -48.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.3% | 5.3% | 2.2% | -7.0% | -3.4% | -10.0% | -10.6% | -7.9% | -39.3% | -64.1% | -56.6% |
| ROA | 4.9% | 4.9% | 2.0% | -6.6% | -3.1% | -9.2% | -9.5% | -6.4% | -23.1% | -34.5% | -35.6% |
| ROIC | 4.4% | 4.4% | 1.3% | -7.2% | -3.3% | -12.0% | -29.8% | -18.8% | -60.0% | -73.1% | -100.3% |
| ROCE | 4.5% | 4.5% | 1.4% | -8.0% | -3.7% | -10.5% | -10.1% | -8.3% | -25.5% | -34.0% | -38.4% |
Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Veracyte, Inc. carries a Debt/EBITDA ratio of 0.7x, which is very conservative (77% below the sector average of 3.0x). The company holds a net cash position — cash of $363M exceeds total debt of $40M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.04 | 0.01 | 0.01 | 0.02 | 0.03 | 0.06 | 0.32 | 0.68 | 0.43 |
| Debt / EBITDA | 0.69 | 0.69 | 1.28 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.25 | -0.16 | -0.20 | -0.13 | -0.14 | -0.80 | -0.61 | -0.66 | -0.23 | -0.57 |
| Net Debt / EBITDA | -5.59 | -5.59 | -4.76 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -2.55 | -2.95 | -5.95 | — | — | — | — | — | — | — |
| Interest Coverage | — | — | 8071.00 | -5719.67 | -207.48 | -339.85 | -154.54 | -22.34 | -11.33 | -5.37 | -10.45 |
Net cash position: cash ($363M) exceeds total debt ($40M)
Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Veracyte, Inc.'s current ratio of 8.15x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 7.81x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 4.66x to 8.15x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.15 | 8.15 | 4.73 | 4.66 | 3.97 | 3.79 | 22.39 | 10.74 | 7.42 | 4.48 | 6.38 |
| Quick Ratio | 7.81 | 7.81 | 4.46 | 4.40 | 3.74 | 3.61 | 22.11 | 10.35 | 7.16 | 4.04 | 6.08 |
| Cash Ratio | 6.89 | 6.89 | 3.68 | 3.53 | 2.86 | 2.76 | 20.82 | 9.12 | 5.97 | 2.82 | 5.13 |
| Asset Turnover | — | 0.37 | 0.34 | 0.32 | 0.26 | 0.18 | 0.26 | 0.44 | 0.76 | 0.91 | 0.64 |
| Inventory Turnover | 7.53 | 7.53 | 6.79 | 7.00 | 7.11 | 6.63 | 8.90 | 5.37 | 9.72 | 5.30 | 7.33 |
| Days Sales Outstanding | — | 31.52 | 38.10 | 40.82 | 54.18 | 68.94 | 57.36 | 58.61 | 52.24 | 64.51 | 49.10 |
Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Veracyte, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 2.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.3% | 1.9% | 0.8% | — | — | — | — | — | — | — | — |
| FCF Yield | 4.4% | 3.7% | 2.1% | 1.7% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $81M | $78M | $73M | $72M | $68M | $53M | $46M | $37M | $34M | $29M |
Peer Comparison
Compare VCYT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VCYTYou | $3B | 44.2 | 44.2 | 22.7 | 70.1% | 11.2% | 5.3% | 4.4% | 0.7 |
 CAI | $33B | -6.2 | 718.4 | 496.4 | — | 5.6% | -93.2% | — | 0.0 |
 ADPT | $3B | -15.2 | — | — | 59.7% | -90.8% | -62.5% | -41.6% | — |
 NAUT | $331M | -5.6 | — | — | — | — | -32.3% | — | — |
 CDIO | $141M | -0.6 | — | — | 100.0% | -23977.9% | -134.0% | -222.7% | — |
 SEER | $103M | -1.3 | — | — | 49.0% | -717.7% | -23.9% | -21.3% | — |
 IMDX | $95M | -1.2 | — | — | 39.3% | -3245.1% | -1480.7% | — | — |
 ASBP | $63M | -5.1 | — | — | — | — | — | — | — |
 YDES | $35M | -15.1 | — | — | 30.4% | -286.5% | -42.7% | -63.3% | — |
 AIMD | $7M | -1.0 | — | — | -153.7% | -66772.2% | -74.4% | -39.8% | — |
 VRAX | $2M | -0.1 | — | — | -838.2% | -97344.8% | -114.4% | -273.2% | — |
| Healthcare Median | — | 23.2 | 14.9 | 19.0 | 65.8% | -6.4% | -36.7% | -13.6% | 3.0 |
Peers based on L4 peer group classification. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See VCYT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VCYT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare VCYT vs CAI
See how VCYT stacks up against sector leader Caris Life Sciences, Inc..
Start ComparisonFrequently Asked Questions
What is Veracyte, Inc.'s P/E ratio?
Veracyte, Inc.'s current P/E ratio is 44.2x. The historical average is 89.5x.
What is Veracyte, Inc.'s EV/EBITDA?
Veracyte, Inc.'s current EV/EBITDA is 44.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 63.3x.
What is Veracyte, Inc.'s ROE?
Veracyte, Inc.'s return on equity (ROE) is 5.3%. The historical average is -57.0%.
Is VCYT stock overvalued?
Based on historical data, Veracyte, Inc. is trading at a P/E of 44.2x. Compare with industry peers and growth rates for a complete picture.
What are Veracyte, Inc.'s profit margins?
Veracyte, Inc. has 70.1% gross margin and 11.2% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Veracyte, Inc. have?
Veracyte, Inc.'s Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.